NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Therapeutic and Monitoring Devices M&A update, 14–28 September 2026

A bi-weekly update on the Therapeutic and Monitoring Devices sector covering public market moves, major product and regulatory news, and the state of the M&A transaction record for September 14–28, 2026. Built for operators, acquirers and advisors tracking where value is being recognized.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Therapeutic and Monitoring Devices Sector Outlook — September 2026

Key figures

Sector median move
-0.4%
9 of 15 covered names, Sep 14–28, 2026
S&P 500 return
+0.8%
same window
Beta Bionics (BBNX) move
+22.7%
two-week price move
Precedent transaction multiple
10.3x
40 recorded deals, EV/LTM EBITDA

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › THERAPEUTIC AND MONITORING DEVICES

Clearance Moves Prices Only When the Annuity Follows

This update covers what moved, what companies announced and where the transaction record stands across September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across September 14–28, 2026, product and regulatory news set the pace for Therapeutic and Monitoring Devices while the transaction record stood still. Nine of 15 covered names fell on a -0.4% median move against a +0.8% S&P 500 return, with Beta Bionics up +22.7% on an FDA clearance and CGM partnership and TriSalus down -8.0% despite its own clearance. No new transactions were announced, leaving the trailing 40-deal precedent set at a median of 10.3x EV/EBITDA as the pricing reference.

Key findings

  • Company news, not transactions, set the pace for price moves this period.
  • Beta Bionics led gains on an FDA clearance and a new CGM partnership.
  • TriSalus fell despite a fresh 510(k) clearance, favoring coverage over dates.
  • No new deals were announced; the 40-deal precedent set remains the reference.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › THERAPEUTIC AND MONITORING DEVICES

    Cover page introducing the Therapeutic and Monitoring Devices bi-weekly industry events and M&A update for September 14–28, 2026.

    We open this update covering the Therapeutic and Monitoring Devices space for September 14–28, 2026, tracking what moved, what companies announced and where the transaction record stands. Over the next pages we walk through the market movers, the period's leading news and the deal record, then close with what it means for the people who act on it.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › THERAPEUTIC AND MONITORING DEVICES Clearance Moves Prices Only When the Annuity Follows This update covers what moved, what companies announced and where the transaction record stands across September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Product and Regulatory News Set the Pace; The Transaction Record Stood Still

    Summarizes the two-week period's market moves, top news drivers and the state of the transaction record.

    Nine of the 15 covered names fell, with a median move of -0.4% against a +0.8% return for the S&P 500, so the softness sat inside this set rather than across the broader market. Beta Bionics led the gains, up +22.7% for the period including +15.3% on Sep 16, following its Sep 14 FDA clearance of the Mint patch pump and a partnership pairing year-long continuous glucose monitoring with the iLet Bionic Pancreas. TriSalus moved the other way, falling -8.0% even after announcing 510(k) clearance for TriNav Advance on Sep 22, which reads as evidence that buyers are pricing coverage breadth and resupply pull-through ahead of the clearance date itself. No new transactions were announced, so the trailing record of 40 precedent deals at a median of 10.3x EV/EBITDA remains the pricing reference — the takeaway is that product and regulatory news, not deal-making, decided this period.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Product and Regulatory News Set the Pace; The Transaction Record Stood Still The two-week period in one page · 15 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 9 of 15 Covered Names Fell; The Median Move Was -0.4% The S&P 500 returned +0.8% over the same window. On NeuraCap's read, the softness sat inside the set rather than across the market, and it was company news that separated the winners from the rest. 2 One Cleared Device and One Monitoring Tie-in Carried the Period's Largest Gain Beta Bionics, Inc. (BBNX) rose +22.7% over the two-week period, including +15.3% on Sep 16. The gain followed the Sep 14 FDA clearance of its Mint patch pump and an announced partnership pairing year-long continuous glucose monitoring with the iLet Bionic Pancreas. 3 A Clearance Did Not Hold the Price at TriSalus TriSalus Life Sciences, Inc. (TLSI) fell -8.0%, including -7.8% on Sep 24, after announcing 510(k) clearance for TriNav Advance on Sep 22. The reaction was consistent with buyers paying for coverage breadth and resupply pull-through rather than for the clearance date. 4 No New Transactions, so the Pricing Reference Is Unchanged No material sector transactions were announced during the period. The trailing record of 40 precedent transactions carries a median of 10.3x EV/EBITDA, against the sector study's CY2027E median of 10.5x. +22.7% Best mover — Beta Bionics, Inc. (BBNX) worst: TLSI -8.0% · 6 up / 9 down of 15 covered -0.4% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    Regulatory Wins Pay When Attach and Pull-Through Follow Them

    Shows the two-week close-to-close price moves for the 15 covered names against the sector median and the S&P 500.

    Across the 15 names we track, the sector median move was -0.4% against a +0.8% return for the S&P 500, with a ±4.6% materiality bar marking which moves stand out. We link each notable move only to the filings and headlines recorded in the window, and where no driver is recorded we say so rather than guess. The pattern we see is that regulatory wins paid off only when attach and pull-through evidence followed them, which is the read we carry into the next page's event detail.

    Everything on this page

    PUBLIC MARKET MOVERS Regulatory Wins Pay When Attach and Pull-Through Follow Them Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -0.4% · S&P 500 +0.8% · materiality bar ±4.6% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -0.4% Beta Bionics, Inc. (BBNX) +22.7% Shares moved following the Sep 14 FDA clearance of the Mint patch pump and the 3D Intelligence dosing algorithm, alongside an announced partnership pairing year-long continuous glucose monitoring with the iLet Bionic Pancreas. A cleared delivery device plus a monitoring integration widens the installed base and the consumable attach behind it. COMPANY-SPECIFIC TriSalus Life Sciences, Inc. (TLSI) -8.0% TriSalus announced 510(k) clearance for TriNav Advance on Sep 22, strengthening its pressure-enabled delivery portfolio for liver embolization; shares moved lower over the days that followed, including -7.8% on Sep 24. Portfolio breadth alone does not reprice a single-indication delivery platform; coding and the allowable do the work. COMPANY-SPECIFIC IRadimed Corporation (IRMD) +5.0% No notable in-window news was identified that clearly explains the move. The +5.0% gain ran ahead of the -0.4% median move across the covered set. Scaled niche franchises can lead the set in a period when broader breadth is soft. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Beta Bionics Dominated the Period's News, on Both Sides of the Story

    Details the period's highest-impact news events, led by Beta Bionics' clearance and partnership announcements.

    Beta Bionics dominated the period's news on both sides of the story: the Sep 14 FDA clearance of its Mint patch pump and an announced partnership combining year-long continuous glucose monitoring with the iLet Bionic Pancreas drove a +22.7% two-week move, including +15.3% on Sep 16. TriSalus also announced 510(k) clearance for TriNav Advance on Sep 22, yet its shares fell -8.0%, including -7.8% on Sep 24. Each event on this page links back to its underlying filing or article, and our 'why it matters' lines are calibrated reads rather than claims. The contrast between these two names is the clearest evidence this period that the market is pricing commercial follow-through, not just regulatory milestones.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Beta Bionics Dominated the Period's News, on Both Sides of the Story The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · PRNewsWire Beta Bionics faced a securities class action with a lead-plaintiff deadline set for November 3 The case runs alongside the period's product news, which is what made the two-week period unusual: good clearance news and an open legal file in the same set of headlines. Product momentum and compliance exposure can sit in the same company at the same time. Sep 15 · NEWS · PRNewsWire A second plaintiffs' firm announced a class action on behalf of Beta Bionics shareholders Multiple filings on the same facts raise the diligence burden on regulatory compliance and product liability, where representations and warranties in this sector concentrate. Escrows and specific indemnities get sized against exactly this kind of open file. Sep 15 · NEWS · GlobeNewsWire Investors were urged to contact counsel ahead of the November 3 lead-plaintiff deadline in the BBNX case The claim period covers shares purchased before the February disclosure, so the matter is anchored in past device performance rather than in the products cleared this period. Buyers separate the legacy file from the current portfolio; sellers should expect both to be priced. Sep 14 · NEWS · GlobeNewsWire Beta Bionics agreed to integrate a year-long continuous glucose monitor with the iLet Bionic Pancreas Interoperability between monitoring and automated delivery is a stated value driver in this sector, and the stated plan is a commercial launch of the integrated system. On NeuraCap's read, integration agreements are doing work that acquisitions used to do. Sep 14 · NEWS · GlobeNewsWire Beta Bionics won FDA clearance for its Mint patch pump and unveiled a next-generation dosing algorithm A cleared patch pump plus a new dosing algorithm extends the installed base and the consumable annuity sitting behind it. That combination is what strategics in this category underwrite. Delivery hardware brings the patient in; resupply pull-through decides what the patient is worth. Sep 14 · NEWS · Newsfile Corp A shareholder-rights firm reminded Beta Bionics purchasers of the pending class action Repeat notices keep the matter visible while the company commercialises new hardware, which shapes how the market weighs the clearance news. Narrative control in this sector runs through evidence and coverage, not through press volume.

  5. 05
    M&A & STRATEGIC ACTIVITY

    The Transaction Record Holds Its Shape While Product News Sets the Pace

    Reports that no new sector transactions were announced, leaving the trailing precedent set as the pricing reference.

    No material sector transactions were announced during September 14–28, 2026, so the transaction record held its shape while product news set the pace. The trailing set of 40 precedent transactions carries a median of 10.3x EV/LTM EBITDA, which we compare against the sector study's CY2027E median of 10.5x. With no new deal evidence added this period, this existing multiple set remains the reference for anyone pricing a transaction in this space today.

    Everything on this page

    M&A & STRATEGIC ACTIVITY The Transaction Record Holds Its Shape While Product News Sets the Pace September 14–28, 2026 · precedent transactions: 40 recorded deals · median 10.3x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record of 40 precedent transactions still anchors the reference set at a median of 10.3x EV/EBITDA. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against 10.3x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

  6. 06
    WHAT IT MEANS

    What the Two-Week Period Changes for Operators, Buyers and Advisors

    Translates the period's events into observations for operators, acquirers and advisors.

    For owners and operators, this period's moves in both directions show that new patient starts, consumable attach rate, resupply pull-through, adherence and wear duration are the KPIs turning a clearance into revenue. For acquirers, the reference set gained product facts but not new prices — the trailing 40 precedents at a median of 10.3x EV/EBITDA sit alongside the study's CY2027E sector median of 10.5x. For advisors, the theme to lead with is clearances arriving without a matching move in the transaction record, evidenced by 9 of 15 covered names falling on a -0.4% median move. Taken together, these observations point toward where value is being recognized in this space right now, without prescribing any single action.

    Everything on this page

    WHAT IT MEANS What the Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 10.5x 17 companies in the study 3 valuation tiers Standing thesis: Three Markets Sit Inside Therapeutic and Monitoring Devices: Platforms, Disposables and Adjacent Service Models FOR OWNERS & OPERATORS Attach and Resupply Turn a Clearance into Revenue Companies in the space traded in both directions on product and regulatory news. The operating KPIs behind those moves are new patient starts, consumable attach rate and resupply pull-through, adherence and wear duration FOR ACQUIRERS The Reference Set Gained Product Facts, Not New Prices With no transactions announced in the window, the trailing 40 precedents at a median of 10.3x EV/EBITDA remain the pricing reference, alongside the study's CY2027E sector median of 10.5x. FOR ADVISORS Lead with Coverage and Annuity Evidence The theme to lead with is clearances arriving without a matching move in the transaction record: 9 of 15 covered names fell; the median move was -0.4%.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources and methodology behind this update's figures and the calibrated language used throughout.

    Every figure in this update is drawn from the recorded universe of prices, filings and transaction records for the covered names, with market data current through September 28, 2026. We source events in a fixed reliability order — SEC filings first, then press releases, then established outlets — and we never draw on video or social platforms. Driver attributions and 'why it matters' reads throughout this deck are calibrated interpretations of that recorded evidence, not assertions of cause, and each figure links back to the record it came from. This structure is what lets a reader trace any number on this page back to its source rather than take it on faith.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Therapeutic and Monitoring Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T161352Z_526_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · globenewswire.com · newsfilecorp.com

Sources and methodology

This update covers Therapeutic and Monitoring Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 15 listed companies whose core business is Therapeutic and Monitoring Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AdaptHealth Corp. (AHCO), Beta Bionics, Inc. (BBNX), BrainsWay Ltd. (BWAY), Delcath Systems, Inc. (DCTH), DexCom, Inc. (DXCM), Enovis Corporation (ENOV), Inogen, Inc. (INGN), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Novocure Ltd (NVCR), Insulet Corp. (PODD), ResMed Inc. (RMD), Tactile Systems Technology, Inc. (TCMD), TriSalus Life Sciences, Inc. (TLSI), Viemed Healthcare, Inc. (VMD). 2 names below the floor were excluded from the statistics: OM, OWLT.

Window and company universe

This update covers Therapeutic and Monitoring Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 15 listed companies whose core business is Therapeutic and Monitoring Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AdaptHealth Corp. (AHCO), Beta Bionics, Inc. (BBNX), BrainsWay Ltd. (BWAY), Delcath Systems, Inc. (DCTH), DexCom, Inc. (DXCM), Enovis Corporation (ENOV), Inogen, Inc. (INGN), IRadimed Corporation (IRMD), KORU Medical Systems, Inc. (KRMD), Novocure Ltd (NVCR), Insulet Corp. (PODD), ResMed Inc. (RMD), Tactile Systems Technology, Inc. (TCMD), TriSalus Life Sciences, Inc. (TLSI), Viemed Healthcare, Inc. (VMD). 2 names below the floor were excluded from the statistics: OM, OWLT.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Therapeutic and Monitoring Devices?

Company valuation reports run the same method against a single business — public or private.